Analysis of COVID-19 mRNA Vaccine-induced Mouth Ulcers Using the Japanese Adverse Drug Event Report Database

There are case reports of mouth ulcers caused by the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine; however, the actual number and characteristics of cases are unknown. Therefore, we examined this issue using the Japanese Adverse Drug Event Report (JADER), a large Japanese database. We calculated the reported odds ratio (ROR) of drugs that may be specifically associated with mouth ulcers and assumed that a signal was present if the lower limit of the calculated ROR's 95% confidence interval (CI) was > 1. In addition, the time to symptom onset after administration of the COVID-19 mRNA and influenza HA vaccines was investigated. We found that the JADER database contained 4,661 mouth ulcer cases between April 2004 and March 2022. The COVID-19 mRNA vaccine was the eighth most common causative drug for mouth ulcers, with 204 reported cases. The ROR was 1.6 (95% CI, 1.4-1.9) and a signal was detected. There were 172 mouthulcer cases associated with the Pfizer-BioNTech's COVID-19 mRNA vaccine, 76.2% of which were female. The outcome was no unrecovered cases with the influenza HA vaccine, whereas the COVID-19 mRNA vaccine showed unrecovered cases (Pfizer-BioNTech: 12.2%, Moderna: 11.1%). The median time-to-onset of the mouth ulcers was two days for the COVID-19 mRNA vaccine and one day for the influenza HA vaccine, indicating that mouth ulcers caused by the COVID-19 mRNA vaccine were delayed adverse events. In this study, the COVID-19 mRNA vaccine was shown to cause mouth ulcers in a Japanese population.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:78

Enthalten in:

Die Pharmazie - 78(2023), 5 vom: 01. Mai, Seite 63-66

Sprache:

Englisch

Beteiligte Personen:

Onoda, T [VerfasserIn]
Tanaka, H [VerfasserIn]
Matsuo, H [VerfasserIn]
Takigawa, M [VerfasserIn]
Satoh, M [VerfasserIn]
Ishii, T [VerfasserIn]

Links:

Volltext

Themen:

COVID-19 Vaccines
Influenza Vaccines
Journal Article
MRNA Vaccines
Pharmaceutical Preparations
RNA, Messenger

Anmerkungen:

Date Completed 17.05.2023

Date Revised 23.05.2023

published: Print

Citation Status MEDLINE

doi:

10.1691/ph.2023.3521

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM356919196